WallStreetZenWallStreetZen

NASDAQ: EXEL
Exelixis Inc Stock

$21.91+0.20 (+0.92%)
Updated Feb 28, 2024
EXEL Price
$21.91
Fair Value Price
$23.36
Market Cap
$6.64B
52 Week Low
$16.15
52 Week High
$24.34
P/E
33.71x
P/B
2.93x
P/S
4.17x
PEG
0.61x
Dividend Yield
N/A
Revenue
$1.83B
Earnings
$207.77M
Gross Margin
96%
Operating Margin
14.07%
Profit Margin
11.4%
Debt to Equity
0.3
Operating Cash Flow
$333M
Beta
0.78
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

EXEL Overview

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EXEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

EXEL ($21.91) is undervalued by 6.2% relative to our estimate of its Fair Value price of $23.36 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
EXEL ($21.91) is not significantly undervalued (6.2%) relative to our estimate of its Fair Value price of $23.36 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
EXEL ($21.91) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EXEL due diligence checks available for Premium users.

Be the first to know about important EXEL news, forecast changes, insider trades & much more!

EXEL News

Valuation

EXEL fair value

Fair Value of EXEL stock based on Discounted Cash Flow (DCF)
Price
$21.91
Fair Value
$23.36
Undervalued by
6.20%
EXEL ($21.91) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EXEL ($21.91) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EXEL ($21.91) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

EXEL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
33.71x
Industry
13.96x
Market
35.52x
EXEL is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
EXEL is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

EXEL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.93x
Industry
6.14x
EXEL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

EXEL price to earnings growth (PEG)

For valuing profitable companies with growth potential
EXEL is good value based... subscribe to Premium to read more.
PEG Value Valuation

EXEL's financial health

Profit margin

Revenue
$479.7M
Net Income
$85.5M
Profit Margin
17.8%
EXEL's Earnings (EBIT) of $257.52M... subscribe to Premium to read more.
Interest Coverage Financials
EXEL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$2.9B
Liabilities
$678.4M
Debt to equity
0.3
EXEL's short-term assets ($1.32B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EXEL's short-term assets ($1.32B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EXEL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EXEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$10.6M
Investing
$61.7M
Financing
-$206.2M
EXEL's operating cash flow ($333.32M)... subscribe to Premium to read more.
Debt Coverage Financials

EXEL vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
EXEL$6.64B+0.92%33.71x2.93x
IONS$6.78B-1.84%-18.18x17.54x
CRSP$7.04B-1.62%-45.20x3.74x
BBIO$6.21B-1.23%-8.93x-4.58x
CYTK$7.17B-9.75%-13.17x-16.33x

Exelixis Stock FAQ

What is Exelixis's quote symbol?

(NASDAQ: EXEL) Exelixis trades on the NASDAQ under the ticker symbol EXEL. Exelixis stock quotes can also be displayed as NASDAQ: EXEL.

If you're new to stock investing, here's how to buy Exelixis stock.

What is the 52 week high and low for Exelixis (NASDAQ: EXEL)?

(NASDAQ: EXEL) Exelixis's 52-week high was $24.34, and its 52-week low was $16.15. It is currently -9.98% from its 52-week high and 35.71% from its 52-week low.

How much is Exelixis stock worth today?

(NASDAQ: EXEL) Exelixis currently has 303,194,259 outstanding shares. With Exelixis stock trading at $21.91 per share, the total value of Exelixis stock (market capitalization) is $6.64B.

Exelixis stock was originally listed at a price of $14.75 in Apr 17, 2000. If you had invested in Exelixis stock at $14.75, your return over the last 23 years would have been 48.54%, for an annualized return of 1.74% (not including any dividends or dividend reinvestments).

How much is Exelixis's stock price per share?

(NASDAQ: EXEL) Exelixis stock price per share is $21.91 today (as of Feb 28, 2024).

What is Exelixis's Market Cap?

(NASDAQ: EXEL) Exelixis's market cap is $6.64B, as of Feb 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Exelixis's market cap is calculated by multiplying EXEL's current stock price of $21.91 by EXEL's total outstanding shares of 303,194,259.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.